A long-time patient advocate has joined the Canada Drug Agency’s (CDA) Board of Directors as their first patient member.
Maureen Smith has a long career as a patient partner, spanning over 25 years and several organizations. Smith has been a member of the Board of Directors for the Canadian Organization for Rare Disorders (CORD). She served as a member of the Canadian Institutes of Health Research as part of their Genetics’ Health Services, Policy and Ethical, Legal and Social Issues Research Priority & Planning Committee. She was also the first layperson on the Canadian Government’s Inter-Agency Advisory Panel for Research Ethics and was the citizen member on the National Placebo Committee.
Congratulations, Maureen!
Maureen has 30 years experience as an educator, and was herself diagnosed with a rare disorder at age eight.
For her full CDA bio, click HERE.